Rh is a protein found on the surface of red blood cells. About 85% of people have it (Rh-positive), and about 15% don’t (Rh-negative). In pregnancy, Rh becomes important when a mother is Rh-negative and her baby is Rh-positive, because the mother’s immune system can treat the baby’s blood cells as foreign invaders and produce antibodies against them. This process, called Rh sensitization, can cause serious problems for the baby if left unmanaged.
Why Rh Status Matters in Pregnancy
Your blood type includes two parts: the letter group (A, B, AB, or O) and the Rh factor (positive or negative). The Rh system is the second most clinically significant blood group system after ABO, and the specific protein that matters most is called the D antigen. When doctors refer to someone as Rh-positive or Rh-negative, they’re talking about whether this particular protein sits on the surface of their red blood cells.
Rh status only becomes a concern in pregnancy when there’s a mismatch: the mother is Rh-negative and the father is Rh-positive, giving the baby a chance of being Rh-positive too. If both parents are Rh-negative, the baby will also be Rh-negative and there’s no issue. If the mother is Rh-positive, there’s no issue regardless of the baby’s type.
How Sensitization Happens
During pregnancy, a mother and baby don’t normally share blood directly. But small amounts of fetal blood can cross into the mother’s bloodstream during labor and delivery, or earlier in pregnancy through events like bleeding, abdominal trauma, or certain procedures. When an Rh-negative mother is exposed to Rh-positive fetal blood cells, her immune system recognizes the D antigen as something foreign and begins producing antibodies against it.
This initial exposure usually doesn’t cause problems right away. The immune response takes time to build, which is why the first pregnancy with an Rh-positive baby is typically unaffected. The danger comes in later pregnancies. Once the mother’s immune system has been “primed,” it can produce antibodies much faster and in much greater quantities. These antibodies are small enough to cross the placenta, where they attack and destroy the baby’s red blood cells.
Several events beyond normal delivery can trigger sensitization:
- Miscarriage, ectopic pregnancy, or induced abortion
- Amniocentesis or chorionic villus sampling (CVS)
- Bleeding during pregnancy
- Abdominal trauma
- Manual turning of a breech baby
- Placental abruption
What Happens to the Baby
When maternal antibodies cross the placenta and attack fetal red blood cells, the result is a condition called hemolytic disease of the fetus and newborn. The severity ranges widely. In mild cases, the baby may have slight anemia. In severe cases, the consequences can be life-threatening.
The destruction of red blood cells causes two main problems. First, anemia: the baby doesn’t have enough red blood cells to carry oxygen effectively. When fetal hemoglobin drops far enough below normal for the gestational age, the baby can develop a condition called hydrops fetalis, marked by widespread swelling, fluid accumulation around the lungs and heart, and fluid buildup in the abdomen. Second, the breakdown of red blood cells releases a waste product called bilirubin. A newborn’s immature liver can’t process the excess bilirubin fast enough, leading to jaundice that appears within the first 24 hours after birth.
If bilirubin levels climb high enough, unbound bilirubin can cross into the baby’s brain and cause a form of brain damage called kernicterus. Long-term consequences of kernicterus include cerebral palsy, hearing loss, impaired eye movement, and permanent intellectual disability. Premature babies and those with existing health instability face the highest risk.
How Rh Problems Are Detected
Rh screening is a routine part of early prenatal bloodwork. Your blood type and Rh status are determined at one of your first prenatal visits. If you’re Rh-negative, a blood test called an indirect Coombs test checks whether your body has already produced antibodies against Rh-positive blood. This test detects antibodies floating freely in your bloodstream that have the potential to attack Rh-positive red blood cells.
If antibodies are detected, the pregnancy is considered sensitized and requires closer monitoring. Doctors track fetal well-being using a specialized ultrasound that measures how fast blood flows through an artery in the baby’s brain. In an anemic baby, the blood becomes thinner, and the heart pumps harder to compensate, both of which cause blood to move faster through this artery. This measurement has a 100% sensitivity for detecting moderate to severe fetal anemia, and its introduction dramatically reduced the need for invasive testing. By taking measurements over several consecutive weeks, doctors can identify which babies are trending toward severe anemia and adjust the monitoring schedule accordingly.
Preventing Sensitization With Rh Immune Globulin
The single most important development in managing Rh incompatibility was the introduction of Rh immune globulin (commonly known by the brand name RhoGAM) in the mid-1960s. This injection contains antibodies against the D antigen that essentially intercept and neutralize any fetal Rh-positive blood cells in the mother’s system before her own immune system has a chance to respond.
The standard prevention protocol involves an injection around 28 weeks of pregnancy, with some protocols adding a second dose around 34 weeks. After delivery, if the baby is confirmed Rh-positive, another dose is given within 72 hours. This postpartum dose prevents sensitization from the larger volume of fetal blood that typically enters the mother’s circulation during birth.
Rh immune globulin is also given after any event that could cause fetal blood to mix with the mother’s, including miscarriage, ectopic pregnancy, amniocentesis, CVS, abdominal trauma, or vaginal bleeding. The injection works only as prevention. Once a mother is already sensitized and producing her own antibodies, Rh immune globulin cannot reverse the process.
The widespread use of this prophylaxis has dramatically reduced Rh-related complications. Still, about 0.27% of susceptible women become sensitized despite the prevention program, typically because protocols weren’t followed completely or because spontaneous sensitization occurred during pregnancy.
When Sensitization Has Already Occurred
If a mother is already sensitized, prevention is no longer an option and the focus shifts to protecting the baby. The pregnancy is monitored more frequently with the brain artery ultrasound measurements described above. Mild cases may only need close observation and early delivery planning.
For severe fetal anemia detected before 35 weeks, the standard treatment is an intrauterine blood transfusion. Under ultrasound guidance, a needle is inserted into a blood vessel in the umbilical cord or the baby’s liver to deliver specially prepared, Rh-negative donor blood directly to the baby. The goal is to raise the baby’s red blood cell levels to a target range that can sustain healthy oxygen delivery. The baby is given medication to minimize movement during the procedure, and the volume of blood transfused is calculated based on the baby’s estimated weight and current blood count. Some babies need multiple transfusions before they’re mature enough to be delivered safely.
After birth, affected babies often need treatment for jaundice, which may include light therapy to help break down bilirubin in the skin. In severe cases, an exchange transfusion, where the baby’s blood is gradually replaced with donor blood, may be necessary to rapidly lower dangerously high bilirubin levels and remove circulating antibodies.
Rh-Negative Prevalence Varies by Population
How common Rh incompatibility is depends partly on where you live. About 17% of people in Britain are Rh-negative, making mismatched pregnancies relatively common in populations of European descent. In Northern India, by contrast, only about 4.3% of the population is Rh-negative. Populations of African and East Asian descent also tend to have lower rates of Rh-negative blood types. This means the clinical significance of Rh screening varies by population, though it remains a universal part of prenatal care in most countries.